Company Announcement no. 2/2013

To: NASDAQ OMX Copenhagen A/S                                                        Hørsholm, Denmark, 5 February 2013

Warrant Programme - New Articles of Association

In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 23 January 2013 issued 20,630,000 warrants for the subscription of nominally DKK 20,630,000 shares in the Company.

The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino                                                 Johnny Stilou

President & CEO                                        EVP, Chief Financial Officer

Mobile: +1 917 647 9107                          Mobile: +45 21 227 227

Email: wjp@veloxis.com                           Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.